Compare Boston Beer Company Inc (SAM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs GeneDx Holdings Corp — how do they compare? Boston Beer Company Inc trades at $163.71 (market cap $1.67B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| SAM | WGS | |
|---|---|---|
Market Cap | $1.67B | $2.56B |
Sector | Consumer Staples | Technology |
52-Week High | $260.05 | $167.51 |
52-Week Low | $161.08 | $34.51 |
Enterprise Value | $1.43B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Boston Beer Company (SAM) trades at $162.06, down 3.98% today, showing mixed signals with bearish technical indicators but positive cash flow trends. Recent earnings have missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains a debt-free balance sheet with strong operating cash flow of $270M in 2025, but faces volume declines and margin pressure.
SAM presents a cautious outlook with analyst consensus leaning Hold (71.87%) despite a $207.33 price target suggesting 28% upside. Key risks include declining alcohol consumption and execution challenges, while opportunities lie in new product launches and marketing leadership changes. The stock's valuation appears reasonable with P/E of 22.66 and P/S of 0.89.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
